Navigation Links
Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
Date:10/30/2007

SAN MATEO, Calif., Oct. 30 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs for chronic and acute diseases, today announced that Donald J. Santel has been appointed to Anthera's Board of Directors.

"Don's experience in transforming early biotech startups into commercial stage organizations will be of benefit as we expand our pipeline and move A-002 into large scale Phase III clinical trials," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "His strategic and operational insights related to the challenges facing development stage companies will be invaluable as Anthera embarks on the next phase of growth."

"We're pleased to have an individual of Don's caliber join our Board of Directors," said Lowell E. Sears Chairman of Anthera's Board of Directors. "We look forward to his contributions that will further shape strategic direction and drive future growth."

Donald J. Santel has 25 years experience in the biotechnology/biopharmaceutical and medical device industries. Most recently, he was Co-Founder and Chief Executive Officer at CoTherix, Inc., where he launched Ventavis(R) Inhalation Solution and led the sale of the company to Actelion Pharmaceuticals, Ltd. in January 2007. Prior to CoTherix, he served as President and Chief Operating Officer of Reflow, and sold the company to Fox Hollow (now EV3) and served as Vice President of Marketing and International Sales at Cardiac Pathways Corporation, a medical device company later acquired by Boston Scientific. Mr. Santel began his career at Medtronic, Inc. Mr. Santel also serves on the board of Hyperion Therapeutics. He has a BSE from Purdue University and an MS in from the University of Minnesota.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held pharmaceutical development company committed to world-class development and commercialization of pr
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. McDonalds: French Fries, Transparent to more Trans -Fats
2. French fries by McDonalds fries in another controversy
3. Hospital Withdraws McDonalds Reward Scheme
4. Fat Content In McDonald’s & KFCs Foods Varies From Country To Countr
5. McDonald Sets Aside Promises of Healthy Menu
6. Bird flu no threat to McDonalds chicken: Advertisement strategy
7. Hepatitis Scare at McDonald’
8. McDonalds to Start Coffee Chain in Japan
9. Study casts doubt on keyboard ills
10. Who Board To Discuss Asian Tsunami Related Health Issues
11. Abdominal Crunches Not The Best Option For Wash Board Abs.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... Physical Activity on Mobility Limitation in Old Age , ... of mobility limitation in old age, whereas leisure-time physical ... study which followed up 5,200 public sector employees for ... Research Center in Finland and the Finnish Institute of ... wears the body and lasts for several hours a ...
(Date:4/23/2014)... have shown that proliferation of endogenous neural precursor ... neurons and axons. From the perspective of neural ... Yat-sen University in China observed the effects of ... cell proliferation and expression of basic fibroblast growth ... brain on the infarct side. The researchers found ...
(Date:4/22/2014)... Government and industry leaders visited the New Jersey ... President Joel S. Bloom for the launch of ... corporation that provides a new model for business ... higher education assets and investment. U.S. Senator Cory ... CEO Joe Taylor, New Jersey Lieutenant Governor Kim ...
(Date:4/22/2014)... provide primary care for low-income patients may ease ... companies while improving patient health, researchers have concluded. ... health clinics that avoid costs associated with insurance ... hospital admission rates and emergency room visits, according ... Altoona. , The researchers estimated that the ...
(Date:4/22/2014)... of pregnancy among women using a newer method of ... times greater over a 10-year period than using the ... at Yale University and UC Davis has found. ... Contraception , the study found the higher risk of ... brand name Essure. , "This study provides essential ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... April 6 (HealthDay News) -- Compared with normal weight ... and infections during and after a hysterectomy, a new ... 20,353 women who had a hysterectomy to treat non-cancerous ... tumors and pain. Women with a body-mass index ...
... able to predict which adults with mild cognitive impairment are ... results of a study published online and in the June ... is an intermediate stage between the decline in mental abilities ... associated with dementia, a group of brain disorders that includes ...
... national prescribing patterns shows that more than half of ... filled another opioid prescription within the previous 30 days. ... at reducing abuse of prescription opioids. Researchers from ... of the National Institutes of Health, will publish results ...
... , TUESDAY, April 5 (HealthDay News) -- For people ... promise, researchers report. The device, surgically placed just ... jolt to the carotid arteries. This is said to ... activation therapy. The researchers were scheduled to present ...
... persistence and recurrence of H5N1 avian influenza in endemic regions ... birds. Trade in poultry, poultry products and caged birds, and ... these areas. Several recent outbreaks of avian influenza have suggested ... the virus over long distances. In a paper ...
... April 5 (HealthDay News) -- The substantial increase in ... emergency departments between 1995 and 2008 highlights the need ... researchers. They analyzed National Hospital Ambulatory Medical Care ... rose from about 330,000 in 1995 to 1.65 million ...
Cached Medicine News:Health News:Weight Linked to Complications in Some Hysterectomy Patients 2Health News:Using MRI, researchers may predict which adults will develop Alzheimer's 2Health News:Analysis of opioid prescription practices finds areas of concern 2Health News:Implantable Device May Lower Tough-to-Treat Hypertension 2Health News:Implantable Device May Lower Tough-to-Treat Hypertension 3Health News:Migratory birds, domestic poultry and avian influenza 2Health News:Migratory birds, domestic poultry and avian influenza 3Health News:As CT Scans of Kids Soar, Experts Urge Oversight 2
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
(Date:1/15/2014)... Jan. 15, 2014  In an unprecedented effort to curb the spread ... and other transport vehicles, an advanced and portable UV germicidal lamp ... the first time. In order to prevent EMS ... pathogens, West Palm Beach Fire Rescue is ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... FRANCISCO, Calif., June 01, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, ... from ongoing clinical,studies of SNS-595 and SNS-032 at ... being held June 7-10, 2007 in Vienna,Austria. , ... Phase 1 clinical trial of SNS-595 in acute ...
... Zurich, June 1, 2007-Cytos Biotechnology AG is ... presentations of its novel,immunotherapeutic CYT003-QbG10 to treat ... were obtained,and will be presented in different ... Academy of Allergology and Clinical Immunology,(EAACI), taking ...
Cached Medicine Technology:Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 2Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 3CYT003-QbG10 to treat allergy to be presented at the Congress of,the European Academy of Allergology and Clinical Immunology,(EAACI), June 9-13, 2007 2
The Accuref 8001 allows you to measure much smaller pupils than conventional units and 3 step Target light adjuster ensures accurate results....
Sterile perfluorocarbon for intraocular Application....
Alcon offers medical grade perfluoropropane (SF6) intraocular gases for ophthalmological use....
Round knurled handle. Overall length 130 mm....
Medicine Products: